Amgen Alters Anemia Drug Discounts

The company is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety.

Read The Full Story

Share: Digg - del.icio.us - Stumble It - News Vine - buzz-it

Source: NY Times Published: Thursday 28th of August 2008

Members: Save This Story